Inactive Instrument

HLS Therapeutics Inc Stock Toronto S.E.

Equities

AM

CA05328X1015

Pharmaceuticals

Sales 2024 * 64.08M 87.58M Sales 2025 * 73.43M 100M Capitalization 108M 148M
Net income 2024 * -20M -27.34M Net income 2025 * -17M -23.24M EV / Sales 2024 * 1.69 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.47 x
P/E ratio 2024 *
-6.33 x
P/E ratio 2025 *
-9.44 x
Employees -
Yield 2024 *
4.36%
Yield 2025 *
-
Free-Float 99.51%
More Fundamentals * Assessed data
Dynamic Chart
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA CI
Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update MT
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022 MT
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million MT
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024 CI
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan MT
HLS Therapeutics Brief: Announcing that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan MT
HLS Therapeutics Inc. Announces CFO Changes CI
HLS Therapeutics Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson MT
HLS Therapeutics Brief: Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson MT
HLS Therapeutics Brief: Adds Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with Placebo MT
HLS Therapeutics Brief: Says New REDUCE-IT Analyses Show Vascepa (Icosapent Ethyl) Associated with 29% Relative Risk Reduction Vs Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline MT
More news
Managers TitleAgeSince
Chief Executive Officer 56 23-04-30
Director of Finance/CFO - 23-06-21
Compliance Officer 43 18-05-06
Members of the board TitleAgeSince
Chairman 46 21-06-17
Director/Board Member 66 19-03-20
Director of Finance/CFO - 23-06-21
More insiders
HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.
Calendar
More about the company